نتایج جستجو برای: chemoimmunotherapy

تعداد نتایج: 698  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Samuel A Jacobs Steven H Swerdlow Jeffrey Kant Kenneth A Foon Rachel Jankowitz Stephanie R Land Nicholas DeMonaco Judith Joyce Jennifer L Osborn Terry L Evans Patricia M Schaefer The Minh Luong

PURPOSE Radioimmunotherapy has been approved for relapsed follicular lymphoma (FL), including rituximab-refractory FL. This study was designed to determine the CR rate with short-course chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended rituximab as first-line treatment. EXPERIMENTAL ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Pierpaolo Correale Pierosandro Tagliaferri Antonella Fioravanti Maria Teresa Del Vecchio Cinzia Remondo Francesco Montagnani Maria Saveria Rotundo Chiara Ginanneschi Ignazio Martellucci Edoardo Francini Maria Grazia Cusi Pierfrancesco Tassone Guido Francini

PURPOSE GOLFIG chemoimmunotherapy regimen proved to be a safe and very active chemoimmunotherapy regimen in advanced colon cancer patients. We have thus investigated the immunobiological feedback to the treatment and its possible correlation with the clinical outcome of these patients. EXPERIMENTAL DESIGN This clinical and immunologic study involved 46 patients, 27 males and 19 females, enrol...

Journal: :European urology 2011
Willem Oosterlinck Ziya Kirkali Richard Sylvester Fernando Calais da Silva Christer Busch Ferran Algaba Sandra Collette Aldo Bono

BACKGROUND Bacillus Calmette-Guérin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS). OBJECTIVE Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS. DESIGN, SETTING, AND PARTICIPANTS In a noncomparative phase 2 study, 96 patients with pri...

Journal: :Cancer research 1983
M B Mokyr S Dray

Mice bearing a large s.c. MOPC-315 tumor can be cured by a dose of cyclophosphamide (CY) ranging from 15 to 200 mg/kg. However, the low (15 mg/kg) and the high (200 mg/kg) doses mediate tumor eradication via different mechanisms. Tumor eradication by the low dose of drug requires the cooperation of the toxic effect of the drug and T-cell-dependent antitumor immunity. On the other hand, tumor er...

Journal: :The Journal of Experimental Medicine 1982
M A Cheever P D Greenberg A Fefer S Gillis

Spleen cells from C57BL/6 mice immunized in vivo with a syngeneic Friend virus-induced leukemia, FBL-3, were specifically activated by culture for 7 d with FBL-3, then nonspecifically induced to proliferate in vitro for 12 d by addition of supernatants from concanavalin A-stimulated lymphocytes containing interleukin 2 (IL-2). Such long-term cultured T lymphocytes have previously been shown to ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید